Cargando…
Immune checkpoints, their control by immunotherapy and ovarian cancer
Immune checkpoints are new targets for manipulation of immunological control over malignant tumors. They provide an important means to manage especially recurrent and refractory cancers and those cancers where there is an unmet need such as recurrent melanoma, renal cell carcinoma and recurrent ovar...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701579/ https://www.ncbi.nlm.nih.gov/pubmed/29180924 http://dx.doi.org/10.5114/wo.2017.70108 |
_version_ | 1783281369644793856 |
---|---|
author | Bose, Chinmoy K. |
author_facet | Bose, Chinmoy K. |
author_sort | Bose, Chinmoy K. |
collection | PubMed |
description | Immune checkpoints are new targets for manipulation of immunological control over malignant tumors. They provide an important means to manage especially recurrent and refractory cancers and those cancers where there is an unmet need such as recurrent melanoma, renal cell carcinoma and recurrent ovarian cancer. As a new development this subject is experiencing rapid progress and multiple avenues are opening up. However, there are many hurdles to overcome, requiring constant updating, especially for students of ovarian cancer, who are looking at it with much hope. |
format | Online Article Text |
id | pubmed-5701579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-57015792017-11-27 Immune checkpoints, their control by immunotherapy and ovarian cancer Bose, Chinmoy K. Contemp Oncol (Pozn) Review Paper Immune checkpoints are new targets for manipulation of immunological control over malignant tumors. They provide an important means to manage especially recurrent and refractory cancers and those cancers where there is an unmet need such as recurrent melanoma, renal cell carcinoma and recurrent ovarian cancer. As a new development this subject is experiencing rapid progress and multiple avenues are opening up. However, there are many hurdles to overcome, requiring constant updating, especially for students of ovarian cancer, who are looking at it with much hope. Termedia Publishing House 2017-09-29 2017 /pmc/articles/PMC5701579/ /pubmed/29180924 http://dx.doi.org/10.5114/wo.2017.70108 Text en Copyright: © 2017 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Review Paper Bose, Chinmoy K. Immune checkpoints, their control by immunotherapy and ovarian cancer |
title | Immune checkpoints, their control by immunotherapy and ovarian cancer |
title_full | Immune checkpoints, their control by immunotherapy and ovarian cancer |
title_fullStr | Immune checkpoints, their control by immunotherapy and ovarian cancer |
title_full_unstemmed | Immune checkpoints, their control by immunotherapy and ovarian cancer |
title_short | Immune checkpoints, their control by immunotherapy and ovarian cancer |
title_sort | immune checkpoints, their control by immunotherapy and ovarian cancer |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701579/ https://www.ncbi.nlm.nih.gov/pubmed/29180924 http://dx.doi.org/10.5114/wo.2017.70108 |
work_keys_str_mv | AT bosechinmoyk immunecheckpointstheircontrolbyimmunotherapyandovariancancer |